Literature DB >> 9109135

Mycobacterial lung disease in cystic fibrosis: a prospective study.

B Fauroux1, B Delaisi, A Clément, C Saizou, D Moissenet, C Truffot-Pernot, G Tournier, H Vu Thien.   

Abstract

BACKGROUND: Patients with cystic fibrosis (CF) may be predisposed to airway infections with unusual organisms, such as mycobacteria. The aim of the study was to determine the incidence and clinical picture of mycobacterial infection in CF children.
METHODS: At least 2 acid-fast bacillus (AFB) smears and mycobacterial cultures were performed on a prospective basis on 682 sputum specimens from 106 patients during a 1-year period.
RESULTS: Thirty-three percent of the cultures were contaminated with other bacteria. Seven children had at least one sputum culture positive for one mycobacterium. Five children had only one positive AFB culture. Their clinical status and lung function remained stable during follow-up. Two teenagers with severe lung disease had several positive AFB smears and cultures for Mycobacterium chelonae and Mycobacterium abscessus. The isolation of M. chelonae and M. abscessus was associated with a clinical and functional decline. Clarithromycin treatment resulted in temporary improvement with the disappearance of the mycobacteria after 6 months of treatment. This prospective study shows an incidence of 2.3% for positive cultures. The prevalence was 6.6% for mycobacterial colonization but only 1.9% for mycobacterial lung disease in our pediatric population.
CONCLUSIONS: We recommend performing AFB smears and cultures in CF children with severe lung disease and/or during a lung exacerbation. In these patients persistence of M. chelonae or M. abscessus in sputum should lead to consideration of treatment with clarithromycin.

Entities:  

Mesh:

Year:  1997        PMID: 9109135     DOI: 10.1097/00006454-199704000-00004

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  25 in total

Review 1.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

2.  Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis.

Authors:  Valerie Waters; Felix Ratjen
Journal:  Cochrane Database Syst Rev       Date:  2020-06-10

3.  Acute respiratory failure involving an R variant of Mycobacterium abscessus.

Authors:  Emilie Catherinot; Anne-Laure Roux; Edouard Macheras; Dominique Hubert; Moussa Matmar; Luc Dannhoffer; Thierry Chinet; Philippe Morand; Claire Poyart; Beate Heym; Martin Rottman; Jean-Louis Gaillard; Jean-Louis Herrmann
Journal:  J Clin Microbiol       Date:  2008-11-19       Impact factor: 5.948

4.  Clinical significance of a first positive nontuberculous mycobacteria culture in cystic fibrosis.

Authors:  Stacey L Martiniano; Marci K Sontag; Charles L Daley; Jerry A Nick; Scott D Sagel
Journal:  Ann Am Thorac Soc       Date:  2014-01

Review 5.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

6.  Fatal pulmonary infection due to multidrug-resistant Mycobacterium abscessus in a patient with cystic fibrosis.

Authors:  M Sanguinetti; F Ardito; E Fiscarelli; M La Sorda ; P D'Argenio; G Ricciotti; G Fadda
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

7.  Intra- and interpatient variability of the hsp65 and 16S-23S intergenic gene region in Mycobacterium abscessus strains from patients with cystic fibrosis.

Authors:  Brigitte König; Ina Tammer; Veronika Sollich; Wolfgang König
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

8.  Age-related prevalence and distribution of nontuberculous mycobacterial species among patients with cystic fibrosis.

Authors:  Catherine Pierre-Audigier; Agnès Ferroni; Isabelle Sermet-Gaudelus; Muriel Le Bourgeois; Catherine Offredo; Hoang Vu-Thien; Brigitte Fauroux; Patricia Mariani; Anne Munck; Edouard Bingen; Didier Guillemot; Gilles Quesne; Véronique Vincent; Patrick Berche; Jean-Louis Gaillard
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

9.  Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria.

Authors:  Richard J Wallace; Barbara A Brown-Elliott; Christopher J Crist; Linda Mann; Rebecca W Wilson
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

Review 10.  Nontuberculous mycobacteria: the changing epidemiology and treatment challenges in cystic fibrosis.

Authors:  Janice M Leung; Kenneth N Olivier
Journal:  Curr Opin Pulm Med       Date:  2013-11       Impact factor: 3.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.